NCT02278796View on ClinicalTrials.gov

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 28, 2018

Study Completion Date

November 30, 2020

Conditions
Lymphoma, Large B-Cell, DiffuseLymphoma, FollicularLymphoma, Mantle-Cell
Interventions
DRUG

BeEAM

Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells

DRUG

BEAM

Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells

Trial Locations (4)

1140

Hanusch Krankenhaus Wien, Vienna

3010

Department for Medical Oncology University Hospital/Inselspital, Bern

4020

Krankenhaus der Elisabethinen Linz, Linz

8091

Universitätsspital Zürich, Zurich

All Listed Sponsors
collaborator

Hanusk Krankenhaus Wien

UNKNOWN

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT02278796 - A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) | Biotech Hunter | Biotech Hunter